(NASDAQ: DYN) Dyne Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Dyne Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast DYN's revenue for 2026 to be $731,895,180, with the lowest DYN revenue forecast at $429,861,157, and the highest DYN revenue forecast at $1,033,929,203. On average, 5 Wall Street analysts forecast DYN's revenue for 2027 to be $15,091,293,995, with the lowest DYN revenue forecast at $7,555,375,434, and the highest DYN revenue forecast at $21,676,314,428.
In 2028, DYN is forecast to generate $63,336,082,178 in revenue, with the lowest revenue forecast at $48,867,295,010 and the highest revenue forecast at $77,804,869,345.